By Daily Mail Reporter and Ap The Food and Drug Administration on Friday approved a long-delayed inhalable diabetes medication to help patients control their blood sugar levels during meals. The FDA cleared MannKind Corp.'s Afrezza, a fast-acting form of insulin, for adults with the most common form of diabetes, which affects more than 25 million Americans. The approval decision comes more than three years after the agency first asked MannKind to run additional clinical studies on the drug. Inhaler: The device, which is about the size of a referee's whistle, could replace injectable insulin Tiny: Other, similar devices have been much larger - some the size of a tennis ball - than the Afrezza device
@highlight
Afrezza is a fast-acting form of insulin that can be inhaled rather than injected - to control blood-sugar levels
@highlight
Diabetes affects more than 25 million Americans
@highlight
Billionaire philanthropist Alfred E. Mann has lost hundreds of millions of dollars developing the drug
Mannkind first submitted the drug to @placeholder in March 2009.